newsfilter
← Latest News
Business Wire·

Sensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual Report

GJB2-GT (SENS-601) CTA/IND-enabling studies progress, supported by regulatory interactions with FDA and EMA since Q3 2025, and on track for CTA submission in H1 2026 SENS-501 Audiogene trial ongoing; six-month